Skip to main navigation Skip to search Skip to main content

First-in-human study of ALK201, a FGFR2b-targeting antibody-drug conjugate (ADC) for patients (pts) with advanced solid tumors.

  • Dan-yun Ruan
  • , Qi Dang
  • , Suxia Luo
  • , Yanqiu Zhao
  • , Udit Nindra
  • , Shou Qing Tang
  • , Haiping Jiang
  • , Jian Liu
  • , Andrew Ohyama Parsonson
  • , Michelle Frances Morris
  • , Lin Xie
  • , Xinjun Liang
  • , Lilin Chen
  • , Rui Meng
  • , Sijuan Ding
  • , Huaqiu Shi
  • , Yong Fang
  • , Meredith Pelster
  • , Yongsheng Li
  • , Rui-Hua Xu

Research output: Contribution to journal › Meeting abstract › peer-review

Original languageEnglish
Article number3025
Number of pages1
JournalJournal of Clinical Oncology
Volume44
Issue number16 Supplement
DOIs
Publication statusPublished - 1 Jun 2026
Event2026 American Society of Clinical Oncology (ASCO) Annual Meeting - Chicago, United States
Duration: 29 May 2026 → 2 Jun 2026

Cite this